Aldosterone blockade: an emerging strategy for abrogating progressive renal disease.
about
Role of the Renin-Angiotensin-Aldosterone System beyond Blood Pressure Regulation: Molecular and Cellular Mechanisms Involved in End-Organ Damage during Arterial HypertensionVascular calcification--is aldosterone a culprit?Mechanisms of disease reversal in focal and segmental glomerulosclerosisAldosterone dysregulation with aging predicts renal vascular function and cardiovascular risk.Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension.Aldosterone: role in the cardiometabolic syndrome and resistant hypertensionSerum potassium and outcomes in CKD: insights from the RRI-CKD cohort studyA randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patientsMitochondrial dysfunction mediates aldosterone-induced podocyte damage: a therapeutic target of PPARγ.Manifestation of renal disease in obesity: pathophysiology of obesity-related dysfunction of the kidneyEndogenous cardiotonic steroids in kidney failure: a review and an hypothesis.Sodium intake, ACE inhibition, and progression to ESRD.The metabolic syndrome and risk of chronic kidney disease: pathophysiology and intervention strategies.Mechanisms of progression of chronic kidney diseaseThe role of aldosterone blockade in murine lupus nephritis.The kidney and cardiovascular risk--implications for management: a consensus statement from the European Society of Hypertension.Effects of p53 on aldosterone-induced mesangial cell apoptosis in vivo and in vitroThe Role of Aldosterone in Obesity-Related Hypertension.Inhibition of the renin-angiotensin system and target organ protection.Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufageninMineralocorticoid receptor activation in obesity hypertension.Superoxide anion and hydrogen peroxide-induced signaling and damage in angiotensin II and aldosterone action.Pathogenesis and therapeutic implications of cardiorenal syndrome.Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics.Parathyroid hormone, a crucial mediator of pathologic cardiac remodeling in aldosteronism.The effect of antihypertensive drugs on chronic kidney disease: a comprehensive review.Aldosterone receptor antagonists: current perspectives and therapiesRenin-angiotensin-aldosterone system blockade in chronic kidney disease: current strategies and a look ahead.Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1.Population Pharmacokinetics of LY2623091 in Patients With Hypertension and Chronic Kidney Disease.Chronic angiotensin receptor blockade suppresses intracardiac angiotensin II in angiotensin II-infused rats.PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy[The role of aldosterone in hypertension].Antifibrotic effects of aldosterone receptor blocker (spironolactone) in patients with chronic kidney disease.Pharmacotherapy: Cardiovascular effects of aldosterone blockade in CKD.The long-term antiproteinuric effect of eplerenone, a selective aldosterone blocker, in patients with non-diabetic chronic kidney disease.Protective effects of mineralocorticoid receptor blockade against neuropathy in experimental diabetic rats.Reactive oxygen species-initiated autophagy opposes aldosterone-induced podocyte injury.Eplerenone potentiates the antiproteinuric effects of enalapril in experimental nephrotic syndrome.
P2860
Q26747017-8621A73A-32F2-4AE2-B112-B1AA0EDD0156Q26851687-8E466EF6-D4DC-4925-A2D0-CC6F007D1666Q27010135-EA3706D6-2921-4A73-9BCB-BEEFC0627A41Q33590710-EB419619-7A03-412C-A9CD-992A6B4D7214Q33667283-4C630675-E9A6-4939-92F6-0F85A2FCC577Q33736838-E1DC7C06-3EF5-4FA0-A951-F58D928C793EQ33827471-0734D1FA-46E5-4BEB-A932-E9CF85C86B60Q34075463-7B51C4D3-2949-4921-9328-099157D242F7Q34839549-A442A2D6-2078-4E6E-B396-212475F689EDQ35026645-96EF3625-2AD1-4230-8903-E2FF4C3BD208Q35541172-C5808291-66F7-4960-945B-FC3A970391ECQ35720736-F072A5CB-1B0B-4974-AACE-52B2A58BF42AQ35864666-3E6297F3-DD6C-4040-963D-CA0FDC0BBC10Q36120044-1584C052-A879-4807-8C76-D5B70D90F220Q36641600-AF15D9B6-D399-452D-961B-A9E4BC5E0F52Q36871027-CAB8554E-00CA-464E-8470-D0FF7E621D41Q36931242-F58A8DDB-0497-4BF7-8BB6-66E4B1477CD5Q36950174-20619F94-ACEA-4ED5-9690-5B3372448ABBQ37406883-508C291B-6769-4F10-AA0D-C0C3C45B681BQ37438192-C0B645DE-03B8-4873-8D1B-CEF3712F2448Q37517178-CDA54348-3DF8-4EB6-9742-5CA5B5C76611Q37792074-33ED24C9-63CB-4EC5-91E4-623C49657508Q37812022-FF336372-79B0-4E70-98CA-D1A1D575747EQ37928127-651E4E25-9627-4A13-91FE-589D34F9DD1BQ37988979-6227E3B8-9B17-4345-94FF-78A27D23CB0BQ38050872-8C047160-3836-4E76-9DFD-1C99471846BAQ38120241-B800D936-59B3-490A-9A4B-86F6D4FE8F5FQ38777543-881CB479-DA77-4BB5-81EA-B9E76CCC0A3BQ38850114-CBA95DEB-4427-4DE3-9103-DE97A2BCA28AQ38987673-DD9822BE-84DD-4721-8307-F45A88E1C345Q42118629-E0F1ADE1-429A-42D4-97EC-6A697BA55AFCQ42672479-DB0AB3FB-A8E8-4A3F-9E35-87B573C98BABQ43137773-F25A2102-0182-4D31-A1B4-2CE9905DD2A2Q43238726-5CB70368-88BF-4EB7-9F13-DBD700018F6BQ43256259-FB8C2B78-C868-4535-AD60-3CEF7BA7E786Q43669248-419AE14F-5EC2-4975-B752-D0D8E857C4F1Q46112470-0055AD2B-6CD0-4D06-9295-67BF6CE7CDEBQ46611165-D4234A15-21B0-4177-9973-43DB73FBEDEBQ46840795-C5F8A3B0-CFB8-4914-8D7F-648CF3F5C876
P2860
Aldosterone blockade: an emerging strategy for abrogating progressive renal disease.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Aldosterone blockade: an emerging strategy for abrogating progressive renal disease.
@ast
Aldosterone blockade: an emerging strategy for abrogating progressive renal disease.
@en
type
label
Aldosterone blockade: an emerging strategy for abrogating progressive renal disease.
@ast
Aldosterone blockade: an emerging strategy for abrogating progressive renal disease.
@en
prefLabel
Aldosterone blockade: an emerging strategy for abrogating progressive renal disease.
@ast
Aldosterone blockade: an emerging strategy for abrogating progressive renal disease.
@en
P1476
Aldosterone blockade: an emerging strategy for abrogating progressive renal disease.
@en
P2093
Murray Epstein
P304
P356
10.1016/J.AMJMED.2006.03.038
P407
P577
2006-11-01T00:00:00Z